Systemic hormonal preparations, excluding sex hormones and insulins, saw a notable increase during acute COVID-19, with usage rising to 69 (72.6%) patients, reflecting a significant role of corticosteroids in managing COVID-19 symptoms. Here, INS is linked to COVID-19.